Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cannabinolic acid is a naturally occurring **small molecule cannabinoid acid** found in cannabis and generally regarded as an oxidative, aromatic degradation product related to tetrahydrocannabinolic acid. It is chemically unstable and readily decarboxylates or otherwise converts to **cannabinol**, which has limited direct development as a distinct pharmaceutical agent. Published literature suggests exploratory bioactivity including potential anticancer, anti-inflammatory, analgesic, antiemetic, anxiolytic, and antidepressant effects, but its **primary pharmacology, molecular targets, and therapeutic mechanism remain insufficiently defined**. Based on the available information, cannabinolic acid appears to be an early-stage research compound rather than a clinically established drug, with no clear evidence of approved products, formal clinical development programs, or standardized manufacturers specific to the isolated molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cannabinolic acid.